优诺联合顺铂治疗晚期非小细胞肺癌35例临床分析  

A Report of Combined Chemotherapy of Vinorelbine and Cisplatin in Treatment of Advanced Stage Non-Small Cell Lung Cancer of 35 Cases

作　　者：寇长元[1] 严丽[1] 许真[1] 石萌[1] 王琪 

机构地区：[1]安康市中心医院肿瘤内科,陕西安康725000

出　　处：《肿瘤基础与临床》2008年第3期228-229,共2页journal of basic and clinical oncology

摘　　要：目的 观察优诺（国产长春瑞滨，NVB）联合顺铂治疗晚期非小细胞肺癌（NSCLC）的疗效及毒副反应。方法 35例晚期NSCLC，应用优诺25mg／m^2 i．vd1,8，顺铂30mg／m^2，i．vd1-3，21～28d为1周期，至少治疗2周期。结果 完全缓解（CR）3例，部分缓解（PR）11例，稳定（SD）15例，进展（PD）6例，有效率40％，主要毒副反应为骨髓抑制、胃肠道反应和静脉炎。结论 优诺联合顺铂治疗晚期NSCLC疗效高，毒副反应可耐受，可作为一线治疗方案。Objective To investigate the effect and toxicity of vinorelbine with cisplatin in the treatment of advanced non-small cell lung cancer. Methods Thirty-five patients with advanced NSCLC were treated with vinorelbine 25 mg/m^2 , i. v d1,8 ; cisplatin 30 mg/m^2 , i. v d1-3, There were 21-28 d every cycle, at least for 2 cycles. Results The overall response rate was 40% with CR 3 cases and PR 11 cases, 15 cases were stable and 6 patients were progressive. The mainly adverse reactions were myelo-suppression, digestive tract reaction and vein inflammation. Conclusions The combination chemotherapy with vinorelbine and cisplatin is an active regimen with tolerable adverse reaction for advanced NSCLC and the first regimen can be adopted.

关 键 词：优诺 顺铂 晚期非小细胞肺癌 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]